Use of Capsazepine and Analogs for Treatment of Cancer

Tech ID:
HSC-1197

A UT Health San Antonio scientist has discovered that local intra-tumoral injection of Capsazepine offers an effective treatment to reduce tumor cell proliferation in solid tumors.  Capsazepine is a known, off-patent, analog of Capsaicin that has been proposed and studied as a TRPV1 antagonist for treatment of pain. 

 

Background:

Capsazepine and analogs have been studied as drug candidates for treatment of pain.  Clinical studies for pain management have utilized intravenous formulations for administration.  Clinical trials were discontinued due to hyperthermia associated with intravenous administration and systemic TRPV1 antagonist activity.  Although Capsazepine has been proposed for alleviation of pain, previous studies have not identified Capsazepine as an effective anti-tumor agent. The discovery that Capsazepine is effective for treatment of solid tumors that can be directly accessed and treated by local injection offers the potential for development of a therapeutic for treatment of OSCC, breast carcinomas, cervical cancer, prostate cancer, head and neck cancers, and other solid tumors accessible and subject to local injection.  Furthermore, the compound may provide effective alleviation of pain associated with these tumors.

 

Use of Capsazepine by local injection into solid tumors offers additional advantages.  Oral cancers and head and neck cancers are frequently inoperable because they invade or are approximated upon critical structures in the head and neck.  Injection of Capsazepine into these tumors may result in reduction of tumor volume and can prevent tumor invasion of nerve bundles and critical structures (such as the carotid artery), which are often fatal complications of oral cancer.  Use of Capsazepine in this way may render an inoperable tumor suitable for surgical intervention.  Additional applications include palliative use for patients who are receiving end-of-life care.

 

Commercial Applications and Advantages:

The novel use of Capsazepine and its analogs is advantageous to several oncology subspecialties, particularly cancers of the head and neck, and has the follwoing benefits over the current standard of care:

  • Novel anti-cancer use for a known, off-patent compound originally directed to pain indications
  • Demonstrated activity in OSCC, as well as breast and prostate cancer cell lines and xenograft models
  • OSCC is the 8th most common cancer in the U.S.; 60% of patients have invasive Stage III or IV disease upon diagnosis, with overall 5-year survival as low as 34%
  • Local injection into solid tumors reduces potential for side effects associated with systemic administration
  • Capsazepine offers tumor reduction and alleviation of pain
  • May offer potential to render inoperable OSCC and head & neck cancers operable
Category(s):
Analgesics
For information contact:
John Fritz
Sr. Business Development Manager
FRITZJA@UTHSCSA.EDU
210-562-4033
Inventors:
Cara Gonzales
Patent Information:

United States - Utility

Patent No.9,642,859

Status: Issued

Keywords: